Savsu’s evo DV containers will be available through World Courier’s 140 offices
Hoping to capture a dominant position in the new wave of cellular and genetic therapies, which often require cryogenic shipping conditions, World Courier and Savsu have announced a partnering agreement. World Courier, a unit of AmerisourceBergen, has a long track record of providing express services for the clinical trials market (and more recently has made some forays into commercial-scale shipping). Savsu has been offering refrigerated (2-8°C) and deep-frozen containers, including both dry ice and liquid nitrogen as sources of cold. Last May, the company introduced evo DV 4 and 10 containers specified for conditions to -196°C, operating on liquid nitrogen.
The joint announcements make mention of Savsu’s cloud-based tracking system which, for cellular therapies, offers “vein to vein” traceability (referring to the use of autologous cells drawn from a patient, processed into a therapeutic drug, and infused back to that patient). How this system will integrate with World Courier’s existing Bio-Star and CTM-Star tracking systems remains to be seen.
BioLife Solutions, a manufacturer of cryopreservative solutions for cells and tissues, is part-owner of Savsu, and with the announcement the two companies have locked in a capitalization agreement.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.